Shares of Adaptive Biotechnologies surged 6.4% in after-hours trading Wednesday after the diagnostics company delivered a quarter that blew past Wall Street expectations on nearly every metric — raising a pointed question about whether the stock's rally prices in what's already happened or what's still coming.
• A $12 Million Revenue Surprise Signals the Test Is Catching On Fast. Adaptive generated revenue of $83.9 million in Q3 , crushing the analyst consensus of $71.57 million . Core MRD revenue — from its blood test that detects leftover cancer cells after treatment — grew 44% excluding lumpy milestone payments, while test volumes jumped 46% year over year to 39,587 tests . That acceleration from 43% volume growth in Q2 and 41% in Q1 shows adoption is speeding up, not plateauing.
• Profitability Arrived a Quarter Early — and That Changes the Math. Adaptive achieved total company profitability with adjusted EBITDA of $14.3 million and free cash flow of $7.7 million . Analysts had expected a loss of roughly $0.09 per share ; the company instead posted net income of $2.8 million, or $0.02 per share . For a biotech that burned $5.3 million in cash as recently as Q1, flipping to cash generation removes a key bear argument about dilution risk. The balance sheet now holds $400.2 million in cash and securities .
• The Top-Line Decline Headline Requires Context. Total revenue still fell 11% year over year because Q3 2025 included a large one-time payment from a now-ended partnership with Genentech. Stripping out that expired deal, revenue grew 39% . Investors should watch whether Adaptive can replace pharma milestone income with recurring clinical test revenue.
• New Cancer Guidelines Could Be the Biggest Catalyst Ahead. Adaptive submitted for an additional Medicare reimbursement bundle for maintenance testing in multiple myeloma, just as national cancer guidelines established a dedicated framework for annual testing during treatment . If Medicare agrees to pay for routine ongoing testing — not just one-time checks — the addressable patient population widens dramatically. Management raised full-year MRD revenue guidance to $276–$286 million, implying 30–35% annual growth .
The stock has now recovered its losses from last week's selloff. The question is whether a diagnostics company growing volumes at 46% and freshly profitable deserves a premium — or whether the Genentech revenue hole and milestone lumpiness warrant caution until the recurring revenue engine proves itself over multiple quarters.